Overview

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The potential role of small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with Parkinson's Disease (PD) has not previously been examined. Our hypothesis was that SBBO is an important contributor to the development of weight loss in individuals with PD. The investigators proposed to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a poorly absorbed antibiotic. The investigators performed a prospective, observational case-control study (Part 1) with an open-label therapeutic component (Part 2). Cases were defined as those PD patients who experienced significant weight loss while Controls were defined as those PD patients who did not experience significant weight loss.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Rifamycins
Rifaximin